VALVULAR HEART DISEASE AND PULMONARY CIRCULATION
|
|
- Jocelin Perkins
- 6 years ago
- Views:
Transcription
1 ESC CONGRESS HIGHLIGHTS VALVULAR HEART DISEASE AND PULMONARY CIRCULATION N. Ajmone Marsan (Leiden, NL) MD, PhD, FESC Conflicts of Interest None
2 CONTENTS Pulmonary arterial hypertension Rheumatic heart disease Mitral regurgitation and aortic stenosis TAVI Mitral valve intervention Tricuspid regurgitation
3 Morbidity and Mortality (%) Griphon study: pulmonary arterial hypertension in congenital heart disease Pulmonary arterial hypertension with repaired shunt lesion (ASD, VSD or PDA) Selexipag (oral selective IP prostacyclin-receptor agonist) Selexipag Placebo 4 No. at Risk 2 Risk reduction 42% Months Placebo Selexipag M. Beghetti (Geneva, CH), FP 692
4 Event Free Survival Joint-intention study: initial oral combination therapy in pulmonary arterial hypertension Mortality, Hospitalization and treatment escalation-free survival Initial Bosentan and Sildenafil p=.12 Initial Bosentan or Sildenafil At risk: Combo: Mono: M. Palazzini, (Bologne, IT), P2782
5 Survival Rate Survival Rate Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension 1 Balloon Pulmonary Angioplasty (n=5) 1 Balloon Pulmonary Angioplasty (n=17),9 Pulmonary Endarterectomy (n=12),9,8,8 Medical Therapy (n=12),7,7, Time (Months), Years S. Darocha, (Otwock, PL), P335 T. Inami, (Tokyo, JP) P 579
6 Mortality (%) Survival REMEDY: 2-year follow-up of the global rheumatic heart disease registry Presentation with Heart Failure,9 1 Without Heart Failure,8 Upper-middle-income countries Low-middle-income countries Low-income countries,5 1 Years 1,5 2 2,5,7 1 Years 2 14 countries, N=3343, median age 28 [18-4] High rates of death, CHF and stroke despite low age for symptomatic patients. Higher mortality for low-income countries and less educated patients Better access to quality tertiary care and optimised use of interventions are likely to improve outcomes. L. Zühlke (Cape Town, SA), FP 5733
7 % of pregnancies ROPAC registry: Pregnancy in women with rheumatic mitral valve disease N=39 6 p=.3 p<.1 p=ns p=ns p=.2 Mild MR (n=43) Maternal mortality: MS: 1 during pregnancy; 2 after pregnancy MR: during pregnancy; 1 after pregnancy 4 Moderate-severe MR (n=65) Mild MS (n=57) Moderate MS (n=17) 2 Moderate-severe MS (n=54) Heart failure Fetal loss Small-forgestational age High risk of heart failure and fetal growth restriction Counselling and close follow-up during and after pregnancy I. Van Hagen, (Rotterdam, NL), FP 686
8 Very severe MR predicts postoperative LV dysfunction after mitral valve repair for primary MV disease N=83 pts with primary MR undergoing MV repair Severe Mitral Regurgitation (Reg Volume 8 ml ) Very Severe Mitral Regurgitation (Reg Volume > 8 ml) p value PREOPERATIVE End-systolic Diameter 3.52 ± ±.54.5 Ejection Fraction.67 ±.1.67 ±.8.91 EROA (cm 2 ).43 ± ±.27 <.1 Regurgitant Volume (ml) 58 ± ±29 <.1 POSTOPERATIVE End-systolic Diameter 3.64 ± ±.54.1 (acute postoperative) Ejection Fraction < 5% 43% 64%.3 LM Laufer-Perl (Tel Aviv,IL), P5541
9 Overall Survival Overall Survival Current aortic stenosis registry All asymptomatic patients AV Vmax 4.5m/s 1 Aortic Valve Replacement 1 Aortic Valve Replacement,8 Initial Conservative,8,6,6 Initial Conservative,4,4,2 p=.33 A C Years after AVR,2 p=.3 A C Years after AVR M. Miyake (Kyoto, JP), P5935
10 Mortality Temporal trends of TAVI outcomes ,4 P= ,3, , Months Evolution from novel technology to mainstream therapy Learning curve, structured program and utilization in lower risk patients, procedural simplification U. Landes (Tel Aviv,IL), P6464
11 ITER registry: Single vs. dual antiplatelet therapy after TAVI N=1364 (Aspirin 65, DAPT 759) 3-day outcome 15 1 (%) Aspirine alone Dual antiplatelet therapy 3 2 (%) Long term outcome Aspirine alone Dual antiplatelet therapy Aspirin alone was associated with reduced risk of major vascular complications and bleedings. No increased risk of prosthetic valve dysfunction, lower risk of peri-procedural complications and all cause mortality. M. Bianco (San Francesco AL CAN, IT), FP 669
12 Event Free Survival EVEREST II REALISM. Edge-to-edge repair: survival by symptoms and discharge MR N = 525 1% Significant functional MR 9% 8% 7% FMR NYHA I/II & Disch MR 2+ FMR NYHA I/II & Disch MR 3+ FMR NYHA III/IV & Disch MR 2+ 6% 5% FMR NYHA III/IV & Disch MR 3+ 4% 3% 2% 1% % Days S. Kar, (Los Angeles, USA), FP 2114
13 % Patients % of population Percutaneous mitral annulopasty (Cardioband) >> >> >> 7 centers N = 5 31 ischemic 19 non ischemic MR Severity 1% 8% 6% 4% 2% % Baseline N= Discharge N=48 3 days N= Months N=34 12 Months N=25 24 Months N= II III NYHA Class P<.5 I II III Baseline 24 months K.H. Kuck, (Hamburg GE), FP 1278
14 Outcome of mitral valve surgery for primary MR with and without tricuspid annuloplasty 287 patients, primary mitral regurgitation Associated TA N=165 (57%) No associated TA N=122 (43%) p value Male gender 6 (36%) 65 (53%).2* Age (years) 61 ± ± Coronary artery disease 7 (4%) 14 (12%).2* TTE Findings Tricuspid annulus (mm) 41±6 37±6.1* Moderate to severe TR 79 (48%) 18 (15%).1* Systolic PAP (mmhg) 53±15 46±15.2* Reduced LVEF (< 5%) 25 (15%) 1 (7%).4* Outcome Death 8 (5%) 16 (13%).1* Major Bleeding 11 (7%) 17 (14%).4* A. Darmon, (Paris, FR), P2768
15 Risk of Death (%) Death and Heart Failure (%) Diuretics in severe secondary tricuspid regurgitation? 5 Patients with moderate-to-severe TR before diuretic therapy 1 1 Improved TR severity (N=15) Improved TR severity (N=15),8 No Improved TR severity (N=35),8 No Improved TR severity (N=35),6,6,4,4,2,2 P= Days P= Days TR decreased in 3% of patients with diuretics without association to a better prognosis Cardiac surgery (when indicated) should not be delayed by diuretic therapy H. L. Doan (Paris, Fr), P2775
16 TAKE HOME MESSAGE VALVULAR HEART DISEASE AND PULMONARY CIRCULATION Pulmonary Arterial Hypertension Potential benefit of initial oral combination therapy Promising role for balloon pulmonary angioplasty in CTEPH GRIPHON: Role for Selexipag in patients with corrected congenital heart disease Valvular Heart Disease Burden of rheumatic disease in general and in pregnancy Prognostic relevance of very severe valve disease Encouraging results for percutaneous treatment of secondary MR (edge-to-edge repair and direct annuloplasty) Improved outcomes with TAVI over time Potential role for single antithrombotic therapy after TAVI Don t forget to treat tricuspid regurgitation
Severe left ventricular dysfunction and valvular heart disease: should we operate?
Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More informationDisclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech
Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular
More informationSONOGRAPHER & NURSE LED VALVE CLINICS
SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction
Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease General Principles Etiology Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationHow does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE
How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? Prof. Patrizio LANCELLOTTI, MD, PhD GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liège, CHU
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationReshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid
Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes
More informationEdwards' solution for patients suffering from tricuspid valve disease
Edwards' solution for patients suffering from tricuspid valve disease R. S. von Bardeleben, MD Head Structural and Heart Valve Center Heart Center Cardiology I, University Medicine Mainz Germany Potential
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationClinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun
Clinical Outcome of Tricuspid Regurgitation David Messika-Zeitoun I have financial relationships to disclose Consultant for: Edwards, Symetis and Valtech Tricuspid Regurgitation is a Common Finding Tricuspid
More informationIs TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationValvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong
Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong Management of valvular heart disease Accurate diagnosis and disease severity Prevention and treatment
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationPulmonary Hypertension: Follow-up in adolescence and adults
Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany
More informationPercutaneous Repair for MR:
Percutaneous Repair for MR: Follow-up and longer term outcomes Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital 16th ANGIOPLASTY SUMMIT TCT Asia Pacific 2011 April 27-29 th Seoul, Korea Ted Feldman
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationAnn Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article
Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical
More informationManagement of Tricuspid Regurgitation
Management of Tricuspid Regurgitation Antonis A. Pitsis, FETCS, FESC Thessaloniki Heart Institute, St. Luke s Hospital, Thessaloniki, GREECE HEART FAILURE 2012 BELGRADE SERBIA Does Tricuspid Regurgitation
More informationPeripartum management of Rheumatic Heart Disease
Peripartum management of Rheumatic Heart Disease Dr James Sartain Director of Anaesthesia & Perioperative Medicine Cairns & Hinterland Hospital & Health Service Talk outline Why (still) talk about RHD
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationTranscatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT
Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationPercutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions
Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationLoad and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic
Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative
More informationValve Disease in the Pregnant Patient
Valve Disease in the Pregnant Patient Julie B. Damp, MD December 6, 2012 VanderbiltHeart.com If single, do not allow marriage. If fertile, do not allow pregnancy. If pregnant, do not allow delivery. If
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationEulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain
Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non
More informationQuality Outcomes Mitral Valve Repair
Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationSESSION D5. The Heart of the Matter: Cardiac Disease in Pregnancy Brad M. Dolinsky, MD, MFM
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION D5 Session Description: The Heart of the Matter: Cardiac Disease in Pregnancy Brad M. Dolinsky, MD, MFM
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationSpotlight on Valvular Heart Disease Guidelines
Spotlight on Valvular Heart Disease Guidelines Aortic Valve Disease Raphael Rosenhek Department of Cardiology Medical University of Vienna Palermo, April 26 th 2018 1998 2002 2006 2007 2008 2012 2014 2017
More informationPREGNANCY AND CONGENITAL HEART DISEASE
PREGNANCY AND CONGENITAL HEART DISEASE SIDDHARTH JADHAV M.D. Assistant Professor of Radiology E.B. Singleton Department of Pediatric Radiology Texas Children's Hospital COMMERCIAL DISCLOSURE - None Objectives
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationSeverity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root
The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh
More informationPERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL
PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of mitral leaflets, 80 Accucinch Annuloplasty system, for mitral regurgitation, 79, 94 95 Accutrak delivery system, for CoreValve
More informationDisclosure Statement of Financial Interest Saibal Kar, MD, FACC
MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationDECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D CARDIOLOGO
DECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D PER IL CARDIOLOGO GUIDELINES IN ASYMPTOMATIC MR ACC/AHA ESC Antonio Miceli Heart Hospital Monasterio Foundation NATURAL/
More informationMITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center
MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE Mitral Valve Regurgitation Mitral Valve Stenosis Mitral Valve Prolapse MITRAL REGURGITATION
More informationLate secondary TR after left sided heart disease correction: is it predictibale and preventable
Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary
More informationESC / EACTS new valvular guidelines- Update
ESC / EACTS new valvular guidelines- Update Yaron Shapira, MD The Dan Sheingarten echocardiography & valve clinic Rabin Medical Center, Beilinson Hospital, Petah-Tiqva Tel-Aviv University ESC valve guidelines
More informationAortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment
Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment Stefanos Karagiannis MD PhD Cardiologist Director Echocardiology Dpt Athens Medical Center ESC 2017
More informationICE: Echo Core Lab-CRF
APPENDIX 1 ICE: Echo Core Lab-CRF Study #: - Pt Initials: 1. Date of study: / / D D M M M Y Y Y Y 2. Type of Study: TTE TEE 3. Quality of Study: Poor Moderate Excellent Ejection Fraction 4. Ejection Fraction
More informationComprehensive Hemodynamics By Doppler Echocardiography. The Echocardiographic Swan-Ganz Catheter.
Comprehensive Hemodynamics By Doppler Echocardiography. The Echocardiographic Swan-Ganz Catheter. Itzhak Kronzon, MD, FASE, FACC, FESC, FAHA, FACP, FCCP North Shore HS, LIJ/Lenox Hill Hospital, New York
More informationPeri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,
More informationWhich Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?
Ann Thorac Cardiovasc Surg 2013; 19: 428 434 Online January 31, 2013 doi: 10.5761/atcs.oa.12.01929 Original Article Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should
More informationTranscatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.
Transcatheter Mitral Valve Interventions: Clinical Indications Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Conflicts of interest: -Consultant for Medtronic -Consultant for Cephea Anatomy of
More informationWorldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates
Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional
More informationUptofate Study Summary
CONGENITAL HEART DISEASE Uptofate Study Summary Acyanotic Atrial septal defect Ventricular septal defect Patent foramen ovale Patent ductus arteriosus Aortic coartation Pulmonary stenosis Cyanotic Tetralogy
More informationMinimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.
Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationChronic Primary Mitral Regurgitation
Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......
More informationCandice Silversides, MD Toronto Congenital Cardiac Centre for Adults University of Toronto Toronto, Canada
PVR Following Repair of TOF Now? When? Candice Silversides, MD Toronto Congenital Cardiac Centre for Adults University of Toronto Toronto, Canada Late Complications after TOF repair Repair will be necessary
More informationPreoperative Evaluation Guidelines and Work up
Preoperative Evaluation Guidelines and Work up Wesley Fiser, MD Disclosures: None 1 Case An 80 year old woman with osteoarthritis of the hip, DM, CKD (Cr 2.1), and HTN is diagnosed with an obstructing
More informationPregnancy and Heart Disease Sharon L. Roble, MD Echo Hawaii 2016
1 Pregnancy and Heart Disease Sharon L. Roble, MD Echo Hawaii 2016 DISCLOSURES I have no disclosures relevant to today s talk 2 Cardiovascular Effects of Pregnancy Anatomic Ventricular muscle mass increases
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationOutcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationGender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences
Gender Differences in Valvular Heart Disease Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Obstacles Interest in gender differences is a relatively new phenomenon Registries/RCT
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationPercutaneous mitral valve repair: current techniques and results
Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information
More information13/06/2018. Rheumatic Mitral Stenosis: What does the ESC Guideline say? Mitral Stenosis: Echo Assessment. Mitral Stenosis ESC Guidance 2017
Rheumatic Mitral Stenosis: What does the ESC Guideline say? Mitral Stenosis: Echo Assessment Dave Northridge Edinburgh Heart Centre Rheumatic mitral stenosis Prosthetic mitral dysfunction Calcific/degenerative
More informationClinical material and methods. Fukui Cardiovascular Center, Fukui, Japan
Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui
More informationAsymptomatic Valvular Disease:
Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationDOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES
THORAXCENTRE DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES J. Roelandt DOPPLER HEMODYNAMICS Intracardiac pressures and pressure gradients Volumetric measurement
More informationΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ
ΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ European Accreditation in TTE, TEE and CHD Echocardiography NOTHING TO DECLARE ATRIAL SEPTAL DEFECT TYPES SECUNDUM
More informationPrimary Mitral Regurgitation
EURO VALVE Madrid News from Valves Guidelines 2012: What s new and Why? Primary Mitral Regurgitation Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology Heart Valve Clinic,
More information2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease
2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair
More informationExercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation
Exercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation Julien Magne, PhD, Kim O Connor, MD, Giuseppe Romano, MD, Marie Moonen, MD, Luc A.
More informationEuro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI
Euro Heart Survey New Programme 2009-2012 Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI Alan Cribier, Rouen, France Andreas Gruentzig Award 2010 Cardiogenic
More informationIndex. B B-type natriuretic peptide (BNP), 76
Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible
More information2) VSD & PDA - Dr. Aso
2) VSD & PDA - Dr. Aso Ventricular Septal Defect (VSD) Most common cardiac malformation 25-30 % Types of VSD: According to position perimembranous, inlet, muscular. According to size small, medium, large.
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationInterventional Updates 2016
nterventional Updates 2016 Matthew Johnson, MD Dual Antiplatelet Therapy (DAPT ) What is the newest. Can they ever make up there minds???? What is new in the world of TAVR 1 New risk MitraClip getting
More informationAortic Regurgitation and Aortic Aneurysm - Epidemiology and Guidelines -
Reconstruction of the Aortic Valve and Root - A Practical Approach - Aortic Regurgitation and Aortic Aneurysm Wednesday 14 th September - 9.45 Practice must always be founded on sound theory. Leonardo
More informationStatus Of The MitraClip: Trials (EVEREST II & COAPT) & FDA
Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,
More informationPercutaneous Valve Interventions. Percutaneous Valve Interventions
Percutaneous Valve Interventions Stanton J. Rowe President, Percutaneous Valve Interventions Edwards is Best Positioned to Capitalize on Percutaneous Valve Opportunities #1 global valve replacement and
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More information